Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that all patients have been enrolled across the Phase 3 Orbit and Cosmic studies evaluating setrusumab

GlobeNewswireApr 30 20:00

Ultragenyx Pharmaceutical: Strong Buy Rating on Growth Prospects and Pipeline Potential

TipRanksApr 30 18:21

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

NOVATO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and

GlobeNewswireApr 26 04:30

Ultragenyx Pharma Is Maintained at Buy by TD Cowen

Ultragenyx Pharma Is Maintained at Buy by TD Cowen

Dow JonesApr 25 01:33

Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen

Ultragenyx Pharma Price Target Raised to $61.00/Share From $59.00 by TD Cowen

Dow JonesApr 25 01:33

TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Raises Price Target to $61

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and raises the price target from $59 to $61.

BenzingaApr 25 01:24